Analyst firms · Barclays · RGNX

Barclays RGNX price target and rating history

REGENXBIO Inc. (RGNX) · Health Care

Barclays rates REGENXBIO Inc. (RGNX) Equal Weight with a $12 price target, as of its latest action on Aug 7, 2026. It has published 3 rating actions on RGNX since September 2021, including 0 upgrades and 1 downgrade.

Current rating
Equal Weight
Price target
$12
Median target, all firms
Too few
Actions on RGNX
3

Barclays price target on RGNX

$82$47$1220222023202420252026
Barclays price target on RGNX, each point a stated target, September 2021 to August 2026.

Every Barclays rating on RGNX

How other firms rate RGNX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
MizuhoOutperform$22Oct 5, 2026
BarclaysEqual Weight$12Aug 7, 2026

Questions about Barclays and RGNX

What is Barclays's price target for RGNX?
Barclays's latest stated price target for REGENXBIO Inc. (RGNX) is $12, from its action on Aug 7, 2026.
What is Barclays's rating on RGNX?
Barclays rates RGNX Equal Weight, a neutral rating, as of Aug 7, 2026.
When did Barclays last change its view on RGNX?
On Aug 7, 2026, Barclays downgrades to Equal Weight from Overweight, price target $12.

More RGNX rating histories

All Barclays ratingsRGNX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.